Player FM 앱으로 오프라인으로 전환하세요!
Biologics for pediatric psoriasis and atopic dermatitis
Manage episode 282817040 series 2356616
In the news:
Pityriasis rosea carries few risks for pregnant women
Adjuvant nivolumab plus ipilimumab shows strong results in resected stage IV melanoma
* * *
Because psoriasis and atopic dermatitis (AD) can greatly affect quality of life in pediatric patients, the development of treatments with low-side effect profiles and less laboratory monitoring is essential. Vincent A. DeLeo, MD, talks to Amy S. Paller, MD, and Jennifer B. Scott, MD, about biologics approved for psoriasis and AD in the pediatric population. “Progressively, we’ve seen the newer biologics being more and more effective in both adults and in children, so we’re able to take some of the more effective ones and apply them to our children and adolescents with psoriasis ... We keep raising the bar in children as well as adults,” Dr. Paller reflects. They also discuss the advantages and pitfalls of biologics versus traditional systemic treatments as well as therapies on the horizon.
Article: https://www.mdedge.com/dermatology/article/231217/atopic-dermatitis/biologics-pediatric-psoriasis-and-atopic-dermatitis
Downloadable PDF: https://cdn.mdedge.com/files/s3fs-public/CT106005224.PDF
* * *
Hosts: Nick Andrews, Vincent A. DeLeo, MD (University of Southern California, Los Angeles)
Guests: Amy S. Paller, MD (department of dermatology and the department of pediatrics, Northwestern University, Chicago) and Jennifer B. Scott, MD (department of dermatology, Northwestern University)
Disclosures: Dr. DeLeo is a consultant for Estée Lauder. Dr. Paller has been an investigator and/or consultant for numerous companies. Dr. Scott reports no conflict of interest.
Show notes by: Allegra Sparta, Melissa Sears
* * *
You can find more of our podcasts at http://www.mdedge.com/podcasts
Email the show: podcasts@mdedge.com
Interact with us on Twitter: @MDedgeDerm
106 에피소드
Manage episode 282817040 series 2356616
In the news:
Pityriasis rosea carries few risks for pregnant women
Adjuvant nivolumab plus ipilimumab shows strong results in resected stage IV melanoma
* * *
Because psoriasis and atopic dermatitis (AD) can greatly affect quality of life in pediatric patients, the development of treatments with low-side effect profiles and less laboratory monitoring is essential. Vincent A. DeLeo, MD, talks to Amy S. Paller, MD, and Jennifer B. Scott, MD, about biologics approved for psoriasis and AD in the pediatric population. “Progressively, we’ve seen the newer biologics being more and more effective in both adults and in children, so we’re able to take some of the more effective ones and apply them to our children and adolescents with psoriasis ... We keep raising the bar in children as well as adults,” Dr. Paller reflects. They also discuss the advantages and pitfalls of biologics versus traditional systemic treatments as well as therapies on the horizon.
Article: https://www.mdedge.com/dermatology/article/231217/atopic-dermatitis/biologics-pediatric-psoriasis-and-atopic-dermatitis
Downloadable PDF: https://cdn.mdedge.com/files/s3fs-public/CT106005224.PDF
* * *
Hosts: Nick Andrews, Vincent A. DeLeo, MD (University of Southern California, Los Angeles)
Guests: Amy S. Paller, MD (department of dermatology and the department of pediatrics, Northwestern University, Chicago) and Jennifer B. Scott, MD (department of dermatology, Northwestern University)
Disclosures: Dr. DeLeo is a consultant for Estée Lauder. Dr. Paller has been an investigator and/or consultant for numerous companies. Dr. Scott reports no conflict of interest.
Show notes by: Allegra Sparta, Melissa Sears
* * *
You can find more of our podcasts at http://www.mdedge.com/podcasts
Email the show: podcasts@mdedge.com
Interact with us on Twitter: @MDedgeDerm
106 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.